UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027581
Receipt number R000031510
Scientific Title Safety and efficacy of neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate and LH-RH agonist for high-risk prostate cancer treated with intensity modulated radiotherapy
Date of disclosure of the study information 2017/05/31
Last modified on 2020/01/06 10:42:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety and efficacy of neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate and LH-RH agonist for high-risk prostate cancer treated with intensity modulated radiotherapy

Acronym

neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate for high-risk prostate cancer

Scientific Title

Safety and efficacy of neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate and LH-RH agonist for high-risk prostate cancer treated with intensity modulated radiotherapy

Scientific Title:Acronym

neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate for high-risk prostate cancer

Region

Japan


Condition

Condition

prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We evaluate biochemical free survival for patients with high-risk prostate cancer who treated with neoadjuvant hormone therapy combined Estramustine Phosphate Sodium Hydrate and LH-RH agonist before intensity modulated radiotherapy

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

biochemical recurrence free survival

Key secondary outcomes

progression free survival, over all survival


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

A principal investigator or subinvestigators make a decision of an agent for neodjuvant hormone therapy. Participants are treated with neoadjuvant hormone therapy for 6 months before intensity modulated radiotherapy. After radiotherapy they are folled for maximum 36 months without any hormone or anticancer agents.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1)PSA>20 or Gleason scores>=8 or Tumor stage T2c~T3(high risk prsotate cancer)
2)patients without history of hormone hterapies
3)ECOG Performance Status:0-1
4)patient's agreement to this study
5)men aged 20 years and older

Key exclusion criteria

1)patinets with another active cancers
2)patinets with severe cardiovascular diseases and diabetis militus
3)patients treated with 5a-reductase inhibitors for prostate hyperplasia
4)patientes treated with adrenocortical steroids
5)patinets with another anticancer agents
6)patients ineligible for this study judged by investigators

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Yoshhide
Middle name
Last name Kawasaki

Organization

Tohoku University Graduate School of Medicine

Division name

Department of Urology

Zip code

9808574

Address

Seiryo-Machi 1-1 Aoba-Ku Sendai

TEL

022-717-7278

Email

kawasaki@uro.med.tohoku.ac.jp


Public contact

Name of contact person

1st name Yoshhide
Middle name
Last name Kawasaki

Organization

Tohoku University Graduate School of Medicine

Division name

Department of Urology

Zip code

9808574

Address

Seiryo-Machi 1-1 Aoba-Ku Sendai

TEL

022-717-7278

Homepage URL


Email

kawasaki@uro.med.tohoku.ac.jp


Sponsor or person

Institute

Tohoku University

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tohoku University Graduate School of Medicine

Address

Seiryo-Machi 1-1 Aoba-Ku Sendai

Tel

022-717-7278

Email

kawasaki@uro.med.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 31 Day


Related information

URL releasing protocol

This study was terminated because there were not any enrolled cases.

Publication of results

Unpublished


Result

URL related to results and publications

This study was terminated because there were not any enrolled cases.

Number of participants that the trial has enrolled

0

Results

This study was terminated because there were not any enrolled cases.

Results date posted

2020 Year 01 Month 06 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

This study was terminated because there were not any enrolled cases.

Participant flow

This study was terminated because there were not any enrolled cases.

Adverse events

This study was terminated because there were not any enrolled cases.

Outcome measures

This study was terminated because there were not any enrolled cases.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2012 Year 12 Month 01 Day

Date of IRB

2017 Year 06 Month 15 Day

Anticipated trial start date

2017 Year 11 Month 30 Day

Last follow-up date

2017 Year 11 Month 30 Day

Date of closure to data entry

2017 Year 11 Month 30 Day

Date trial data considered complete

2017 Year 11 Month 30 Day

Date analysis concluded

2017 Year 11 Month 30 Day


Other

Other related information



Management information

Registered date

2017 Year 05 Month 31 Day

Last modified on

2020 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031510


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name